These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17853505)

  • 1. Drug price reform in the UK: debunking the myths.
    Thornton S
    Health Econ; 2007 Oct; 16(10):981-92. PubMed ID: 17853505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OFT, VBP: QED?
    Claxton K
    Health Econ; 2007 Jun; 16(6):545-58. PubMed ID: 17535009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. If it ain't broke, don't price fix it: the OFT and the PPRS.
    Towse A
    Health Econ; 2007 Jul; 16(7):653-65. PubMed ID: 17595047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Straight talk with... Mark Sculpher. Interview by Kate Ravilious.
    Sculpher M
    Nat Med; 2012 Sep; 18(9):1315. PubMed ID: 22961148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Operationalizing value-based pricing of medicines : a taxonomy of approaches.
    Sussex J; Towse A; Devlin N
    Pharmacoeconomics; 2013 Jan; 31(1):1-10. PubMed ID: 23329588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
    Freemantle N
    Health Policy; 1999 Mar; 46(3):255-65. PubMed ID: 10351671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutical policy reform in the Russian Federation.
    Rudisill C; Vandoros S; Antoun JG
    J Health Polit Policy Law; 2014 Jun; 39(3):691-705. PubMed ID: 24603082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
    Persson U; Svensson J; Pettersson B
    Appl Health Econ Health Policy; 2012 Jul; 10(4):217-25. PubMed ID: 22676213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of Value-based Pricing for Medicines.
    Jommi C; Armeni P; Costa F; Bertolani A; Otto M
    Clin Ther; 2020 Jan; 42(1):15-24. PubMed ID: 31882225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pricing medicines: theory and practice, challenges and opportunities.
    Gregson N; Sparrowhawk K; Mauskopf J; Paul J
    Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value-based pricing of drugs in the UK.
    Webb DJ; Walker A
    Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
    [No Abstract]   [Full Text] [Related]  

  • 17. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
    Towse A
    Br J Clin Pharmacol; 2010 Sep; 70(3):360-6. PubMed ID: 20716236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agreement on branded drugs for the NHS.
    Naci H; Dixon J
    BMJ; 2019 Jan; 364():l266. PubMed ID: 30658964
    [No Abstract]   [Full Text] [Related]  

  • 20. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.